<?xml version="1.0" encoding="UTF-8"?>
<ref id="B4">
 <label>4.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Klein</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Stolk</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>De Bruin</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Leufkens</surname>
    <given-names>HGM</given-names>
   </name>
   <name>
    <surname>Crommelin</surname>
    <given-names>DJA</given-names>
   </name>
   <name>
    <surname>De Vlieger</surname>
    <given-names>JSB</given-names>
   </name>
  </person-group>. 
  <article-title>The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: observations and recommendations</article-title>. 
  <source>Eur J Pharmaceut Sci</source>. (
  <year>2019</year>) 
  <volume>133</volume>:
  <fpage>228</fpage>â€“
  <lpage>3</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.ejps.2019.03.029</pub-id>
  <?supplied-pmid 30953753?>
  <pub-id pub-id-type="pmid">30953753</pub-id>
 </mixed-citation>
</ref>
